Conference Coverage

Five pearls target wound healing


 

EXPERT ANALYSIS FROM ODAC 2018

Two technologies still look good for scarless donor sites

Epidermal grafting and technology based on fractional laser treatments continue to show promise for achieving a scarless donor site for patients who need grafting to promote wound healing, Dr. Kirsner said.

As pointed out in a previous report in Dermatology News, avoiding the need for donor site anesthesia is one advantage of the epidermal grafting technique. In addition, the procedure is generally bloodless because the device does not go deep enough to reach the blood vessels, Dr. Kirsner said. In addition, healing of the donor site can be seen on histology in as little as 2 days.

Transferring the epidermis can promote healing because it also transfers keratinocytes and melanocytes to the wound.

“This technique is also excellent to add skin or cells to someone with pyoderma gangrenosum,” Dr. Kirsner said. “Because of the simplicity and the lack of trauma, you don’t get the pathergy you normally see on someone with pyoderma gangrenosum.”

An Autologous Regeneration of Tissue or ART device that transfers columns of healthy skin to a wound to help regenerate tissue and promote healing is a second technology with a lot of potential, Dr. Kirsner said. “With a fractional laser, you create a hole, and that hole heals without scarring. Instead of making holes, R. Rox Anderson, MD, professor of dermatology at Harvard University, Boston, created a device that picks out the microcolumns of skin.” When these full skin thickness columns of skin are transferred to a wound, Dr. Kirsner noted, “in 3 weeks you can pretty much have no visible or a much improved cosmetic scar. Histologically you don’t see a scar either.”

Dr. Kirsner said he had no relevant financial disclosures.

Pages

Recommended Reading

FDA is investigating Zecuity sumatriptan patch for reports of serious burns
MDedge Dermatology
CDC confirms first cases of locally transmitted Zika in continental U.S.
MDedge Dermatology
Statin use increases risk of herpes zoster
MDedge Dermatology
Strontium, ketamine target troublesome itch
MDedge Dermatology
FDA approves first specific treatment for giant cell arteritis
MDedge Dermatology
FDA asks drug maker to shelve Opana ER
MDedge Dermatology
Pain often persists despite biologic treatment in PsA
MDedge Dermatology
Diagnosing high-risk keratinocyte carcinomas in the dermatology clinic
MDedge Dermatology
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Dermatology
In close vote, advisory panel prefers Shingrix over Zostavax
MDedge Dermatology